Delisting risk
Radiopharm Theranostics (ADR) (RADX)
Develops targeted radiopharmaceutical diagnostics and therapies for solid tumors.
$2.02
Pre-market−0.11 (−5.16%)
At close$2.13(−6.17%)
In millions of USD, except per-share figures · converted from AUD at the latest rate
| In millions | Q2 FY25Dec 2025 | Q4 FY25Jun 2026 |
|---|---|---|
| Revenue | 1 | 1 |
| Cost of revenue | 2 | 1 |
| Gross profit | −1 | 0 |
| 21 | 29 | |
| Research & development | 14 | 0 |
| Selling, general & administrative | 7 | 5 |
| Other expenses | 0 | 24 |
| Operating income | −22 | −29 |
| −1 | 8 | |
| Interest income | 0 | 0 |
| Interest expense | 0 | 0 |
| Income before tax | −23 | −21 |
| Income tax expense | −3 | 0 |
| Net income from continuing operations | −20 | −21 |
| Other adjustments | 0 | 0 |
| Net income | −19 | −21 |
| EPS, basic | −$485.47 | −$524.31 |
| EPS, diluted | −$485.47 | −$524.31 |
| Weighted average shares, basic | 0 | 0 |
| Weighted average shares, diluted | 0 | 0 |
| EBITDA | −21 | −29 |
| Depreciation & amortization | 1 | 0 |
| EBIT | −22 | −29 |